| Symbol | AMLX |
|---|---|
| Name | AMYLYX PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 43 THORNDIKE STREET, CAMBRIDGE, Massachusetts, 02141, United States |
| Telephone | +1 617 682-0917 |
| Fax | — |
| — | |
| Website | https://www.amylyx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Additional info from NASDAQ: |
New Form ARS - Amylyx Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-171809 <b>Size:</b> 1 MB
Read moreNew Form DEFA14A - Amylyx Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-171803 <b>Size:</b> 849 KB
Read moreNew Form DEF 14A - Amylyx Pharmaceuticals, Inc. <b>Filed:</b> 2026-04-23 <b>AccNo:</b> 0001193125-26-171800 <b>Size:</b> 4 MB
Read moreAmylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
Read moreNew Form SCHEDULE 13G/A - Amylyx Pharmaceuticals, Inc. <b>Filed:</b> 2026-03-26 <b>AccNo:</b> 0000102909-26-000598 <b>Size:</b> 7 KB
Read moreAmylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia
Read moreCohen Joshua B 🟢 acquired 622.2K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.10 ($5.3M) Transaction Date: Mar 05, 2026 | Filing ID: 098440
Read moreMazzariello Gina 🟢 acquired 186.7K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.10 ($1.6M) Transaction Date: Mar 05, 2026 | Filing ID: 098439
Read moreFRATES JAMES M 🟢 acquired 240.0K shares (1 derivative) of Amylyx Pharmaceuticals, Inc. (AMLX) at $14.10 ($2.0M) Transaction Date: Mar 05, 2026 | Filing ID: 098438
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06747468 | Avexitide for Treatment of Post-Bariatric Hypoglycemia | Phase3 | Post Bariatric Hypoglycemia | Active_Not_Recruiting | 2025-04-29 | 2026-10-01 | ClinicalTrials.gov |
| NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Phase1 | ALS | Recruiting | 2025-04-07 | 2027-10-01 | ClinicalTrials.gov |
| NCT06122662 | AMX0035 and Progressive Supranuclear Palsy | Phase2 | Progressive Supranuclear Palsy | Active_Not_Recruiting | 2023-12-21 | 2029-11-30 | ClinicalTrials.gov |
| NCT05676034 | AMX0035 in Adult Patients With Wolfram Syndrome | Phase2 | Wolfram Syndrome | Active_Not_Recruiting | 2023-03-03 | 2026-12-31 | ClinicalTrials.gov |
| NCT05619783 | Extension Study Evaluating The Safety And Tolerability of AMX0035 | Phase3 | Amyotrophic Lateral Sclerosis | Completed | 2022-12-29 | 2024-10-30 | ClinicalTrials.gov |
| NCT04987671 | Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | Phase1 | ALS | Unknown | 2021-08-05 | 2023-09-01 | ClinicalTrials.gov |
| NCT03533257 | Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment… | Phase2 | Alzheimer Disease | Completed | 2018-09-14 | 2020-11-06 | ClinicalTrials.gov |
| NCT03127514 | AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Phase2 | Amyotrophic Lateral Sclerosis | Completed | 2017-06-22 | 2019-11-24 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Avexitide | DRUG | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| AMX0114 | DRUG | Phase PHASE1 | ALS | RECRUITING | NCT06665165 |
| Placebo | OTHER | Phase PHASE3 | Post Bariatric Hypoglycemia | ACTIVE_NOT_RECRUITING | NCT06747468 |
| AMX0035 | DRUG | Phase PHASE2 | Progressive Supranuclear Palsy | ACTIVE_NOT_RECRUITING | NCT06122662 |